FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
Details
More Products & Services
People
Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience
Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery
Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients
Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS
- New designation broadens potential use of vaccine as treatment for glioma
- Nationwide trials continue in adults, children with some brain tumors
- Development of SurVaxM made possible by community donations
- New designation broadens potential use of vaccine as treatment for glioma
- Nationwide trials continue in adults, children with some brain tumors
- Development of SurVaxM made possible by community donations
Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link